Bristol-Myers Squibb Co.
Most Recent
How Did Tesla Become Renaissance Technologies’ Gem?
In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
Bristol-Myers Squibb Earnings: Time to Buy BMY Stock?
Since my last article about Bristol-Myers Squibb (BMY), the stock has risen from $50.22 to $57.96. Should you buy BMY on today’s Q3 earnings beat?
Could the Fed Trigger an S&P 500 Crash This Week?
The S&P 500 Index, which is trading close to an all-time high, could be affected by the Fed’s tone in its upcoming meeting.
Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
Bristol-Myers Squibb: Could BMY Stock Surge Higher?
Is Bristol-Myers Squibb stock undervalued, and could it surge higher anytime soon? Find out why further upside is possible for BMY.
Amgen and Celgene’s Otezla Deal: Key Highlights
On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
What to Expect From Bristol-Myers Squibb in Q2
Bristol-Myers Squibb will release its second-quarter earnings on Thursday. The revenues will likely rise 7.16% YoY to $6.11 billion in the second quarter.
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
In the latest update on the pending merger with Celgene (CELG), Bristol-Myers Squibb (BMY) proposed plans to divest Otezla—Celgene’s top-selling non-biologic psoriasis drug.
Bristol-Myers Squibb’s Oncology Treatment Growth Drivers
Revenue for Bristol-Myers Squibb’s (BMY) Opdivo has grown by a double-digit percentage YoY (year-over-year) since 2016.
Comparing PFE’s and BMY’s Immunology Drugs
Pfizer’s (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Comparing PFE’s and BMY’s Expense Trends
Pfizer (PFE) has guided for fiscal 2019 adjusted costs of sales as a percentage of revenue of 20.8%–21.8%, and adjusted selling, informational, and administrative expenses of $13.5 billion–$14.5 billion.
How PFE’s and BMY’s EPS Trends Compare
In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.
Comparing PFE’s and BMY’s Revenue Trajectory
Pfizer (PFE) has guided for its revenue falling 1.2% YoY (year-over-year) to $52.0 billion–$54.0 billion in fiscal 2019, whereas analysts expect the company’s revenue to fall 0.55% to $53.35 billion.
What Analysts Recommend for Pfizer and Bristol-Myers Squibb
This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let’s take a closer look at each.
How Will Bristol-Myers Squibb’s Immunology Portfolio Evolve?
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to make the combined company a top-five player in the I&I (immunology and inflammation) space.
What to Expect from Bristol-Myers Squibb’s Oncology Portfolio
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to result in a dominant player in IO (immuno-oncology), solid tumors, and hematology segments.
A Look at Bristol-Myers Squibb’s Near-Term Product Launches
Bristol-Myers Squibb (BMY) highlighted the possibility of six new-term product launches after the completion of the acquisition of Celgene (CELG).
What to Expect from BMY’s Portfolio after Celgene Acquisition
Bristol-Myers Squibb (BMY) estimated the value of currently marketed products of the combined company after completion of the acquisition of Celgene (CELG) to be $55 billion.
Bristol-Myers Squibb Guides for Robust Rise in Revenues and EPS
Bristol-Myers Squibb has guided for more than $45 billion of free cash flow in the first three years after completion of the deal.
What Investors Should Know about BMY-CELG Deal
Bristol-Myers Squibb (BMY) issued a press release announcing shareholder approval of its proposed acquisition of Celgene in April.
Bristol-Myers Squibb Reiterates Non-GAAP EPS Guidance for 2019
Analysts expect Bristol-Myers Squibb’s non-GAAP EPS to rise 5.27% YoY (year-over-year) to $4.19 in 2019.
Bristol-Myers Squibb Reduces Its Gross Margin Guidance for 2019
Gross margin forecasts In its first-quarter earnings press release, Bristol-Myers Squibb (BMY) revised its GAAP (generally accepted accounting principles) and non-GAAP gross margin guidance for 2019 downward from 70%–71% to 70%. Analysts expect Bristol-Myers Squibb’s adjusted gross margin to contract 77 basis points YoY (year-over-year) to 70.21% in 2019, to contract eight basis points YoY […]
Bristol-Myers Squibb Reiterates Its 2019 Revenue Guidance
In its first-quarter earnings press release, Bristol-Myers Squibb (BMY) reiterated its mid-single-digit YoY (year-over-year) worldwide revenue growth expectation for 2019.
Where Analysts Stand on BMY after Its Q1 Earnings Results
Bristol-Myers Squibb (BMY) announced its first-quarter earnings results before the market opened on April 25.
What Analysts Recommend for Bristol-Myers Squibb and Celgene
The current consensus analyst recommendation for Bristol-Myers Squibb is a “buy.”
What’s the Latest on the BMY-Celgene Deal?
Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.
How Novartis Is Transforming Its Structure in 2019
Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.
How Novartis and BMY’s Dividend Profiles Stack Up
In fiscal 2018, Novartis (NVS) and Bristol-Myers Squibb (BMY) reported an annual dividend per share of $2.85 and $1.60, respectively.
NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?
According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
What Are Analysts Recommending for Merck after Q4 2018 Results?
Of the 15 analysts covering Merck, six recommend a “strong buy,” seven recommend a “buy,” and two recommend a “hold.”
Bristol-Myers Squibb’s Revenue Forecast for Fiscal 2019
In fiscal 2018, Bristol-Myers Squibb (BMY) reported revenues of $22.56 billion—a rise of 8.59% YoY (year-over-year).
Bristol-Myers Squibb Releases Strong Q4 Results
On January 24, in Bristol-Myers Squibb’s fourth-quarter earnings release, the company announced fiscal 2018 revenues of $22.56 billion.
Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.
Key Growth Drivers for Bristol-Myers Squibb Going Forward
Bristol-Myers Squibb (BMY) will target four major therapeutic areas after completing the acquisition of Celgene (CELG).
BMY and Celgene to Form a Leading Global BioPharma Company
According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.
Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years
According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.
What to Expect from Bristol-Myers Squibb’s Earnings in 2019
Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3.05 to $3.15 and non-GAAP EPS in the range of $3.80 to $3.90 for fiscal 2018.
How Bristol-Myers Squibb’s Revenues Look Heading into 2019
In its third-quarter earnings conference call, Bristol-Myers Squibb (BMY) has forecasted high-single-digit YoY revenue growth for fiscal 2018.
What to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Let’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance
Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.
Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth
In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.
Analyzing Pfizer’s Revenues in December
Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.
Opdivo: Growth Trajectory in Lung Cancer Indication
Bristol-Myers Squibb’s (BMY) Opdivo reported total revenues of $1.79 billion in the third quarter, which is a rise of 42% YoY.
Opdivo: Second-Line Lung Cancer Market Trends
Bristol-Myers Squibb expects the contribution of lung cancer indication to Opdivo’s US market revenues to be close to 35%.
Bristol-Myers Squibb’s Revenue Projections for Fiscal 2018
Analysts expect Bristol-Myers Squibb to report revenues of $22.56 billion in fiscal 2018, which will be a rise of 8.58% YoY.
Pfizer Stock Has Risen ~20% in 2018
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.
Gilead Sciences: Analysts’ Recommendations
In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.
Analyzing Gilead Sciences’ HIV Portfolio
Gilead Sciences’ HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter.
Merck’s Virology Segment after the Third Quarter
Merck & Co.’s (MRK) Zepatier reported revenues of $104 million in the third quarter compared to $468 million in the third quarter of 2017.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
A Look at the Performances of BMY’s Established Brands
The sales of Bristol-Myers Squibb’s Baraclude fell from $264.0 million in the third quarter of 2017 to $175.0 million in the third quarter of 2018.
GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates
Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.
Bristol-Myers Squibb Reports Q3 2018: Revenues, Product Sales Up
Bristol-Myers Squibb (BMY) reported its third quarter of fiscal 2018 results on October 25. Its total revenues increased to $5.69 billion.
Allergan’s Q3 2018 Earnings: Analysts’ Estimates
Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.
Johnson & Johnson’s Oncology Business Saw Solid Growth in Q3
Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.
Pfizer: Analysts Expect Revenue Growth in Q3
Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.
Pfizer’s Dividends and Earnings Quality
Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.
How Alexion Pharmaceuticals Is Positioned in October
In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.
Merck’s Keytruda Witnessed Solid Growth in First Half of 2018
In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth.
Amgen’s Repatha and Blincyto: How They Did in 3Q17
In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.
A Look at the Performance of Novartis’s Alcon
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.
Gilead Sciences Stock: Analysts’ Recommendations
In October, 18 analysts gave Gilead Sciences stock a “buy” or higher rating, while ten analysts gave the stock a “hold” rating.
How’s Gilead Sciences Positioned in October?
For Gilead Sciences (GILD), falling revenues and recent gains in the stock price have kept investors interested in the stock.
Exploring Seattle Genetics’ Operational Performance
Seattle Genetics (SGEN) incurred a cost of sales of $13.16 million in the second quarter—compared to $8.06 million in the second quarter of 2017.
Analyzing Seattle Genetics’ Key Collaborations
Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.
Seattle Genetics: Impact of the Cascadian Acquisition
Seattle Genetics acquired clinical-stage biopharmaceutical company Cascadian in March for $614.1 million at $10.0 per share.
How Did Pfizer Stock Fare in Q3 2018?
Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”
How Did Pharmaceutical ETFs Perform in Q3 2018?
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
Eli Lilly’s Earnings Quality and Dividend Performance
Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.
Eli Lilly’s Stock Performance in September
Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.
Here’s What Verastem’s Valuation Trend Indicates
Of the seven analysts covering Verastem (VSTM) in September, two have given the stock a “strong buy” rating, and five have given it a “buy.”
A Look at Pfizer’s Market Cap and Shareholding Pattern
The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.
Assessing Pfizer’s Global Performance
Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.
A Closer Look at the Allergan–Bonti Deal
On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
How Is Merck’s Keytruda Positioned in September?
Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion.
uniQure: Its Promising Research Pipeline
uniQure (QURE) is advancing a pipeline of gene therapies that are developed internally and externally. It has a collaboration with Bristol-Myers Squibb (BMY).
Pfizer Announces Results for JAVELIN Renal 101 Study
Pfizer (PFE) and Merck announced in a press release today positive top-line results for their JAVELIN Renal 101 study, which evaluated a combination of Bavencio (avelumab) and Inlyta (axitinib).
Alcon to Set Up Future Global Headquarters in Geneva
Alcon, the eyecare business of Novartis (NVS), includes surgical products and vision care products. It announced today that it will locate its future headquarters in Geneva after spinning off from Novartis.
Pfizer’s PF-06651600 Receives a Breakthrough Therapy Designation
In a press release on September 5, Pfizer announced that the FDA had granted a breakthrough therapy designation to its drug PF-06651600.
Analysts Are Bullish on Zoetis Stock
Of the 18 analysts covering Zoetis (ZTS) in September, 11 analysts gave Zoetis stock a “buy,” or higher rating, and seven analysts gave it a “hold” rating.
A Look at Eli Lilly’s Neuroscience Products in Q2 2018
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes neuroscience products such as Cymbalta, Strattera, and Zyprexa.
Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes oncology products such as Alimta, Cyramza, Erbitux, Lartruvo, and Verzenio.
Pfizer’s Stock Performance in August
Of the 21 analysts tracking Pfizer (PFE) on August 29, one recommended a “strong buy,” nine gave it a “buy,” and eight recommended a “hold.”
Alcon Voluntarily Withdraws CyPass Micro-Stent from Global Market
On August 29, Alcon announced that it had voluntarily withdrawn the CyPass Micro-Stent on a global basis, effective immediately.
EC Approves Amgen’s Blincyto for Pediatric Patients
Today, Amgen (AMGN) announced EC approval of Blincyto for pediatric patients with Philadelphia chromosome-negative CD19 positive refractory.
Novartis’s Business Segments in Q2 2018
Sandoz, Novartis’s generic pharmaceuticals business, reported nearly flat revenues at ~$2.46 billion in Q2 2018.
Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge
Roche’s (RHHBY) Tarceva generated revenues of 298.0 million Swiss francs in H1 2018 compared to 436.0 million Swiss francs in H1 2017.
Xtandi Trials: Pfizer and Astella Amend the Protocols
Xtandi is a prescription drug that treats prostate cancer. Xtandi patients aren’t responding to the medical or surgical therapies that lower testosterone.
Multiple Product Pipeline Catalysts Bode Well for NKTR
In July, Nektar Therapeutics’ (NKTR) new drug application (or NDA) for NKTR-181 was accepted for filing by the FDA.
Eli Lilly Raised Its Non-GAAP Earnings Guidance for Fiscal 2018
In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 non-GAAP EPS guidance to $5.40–$5.50.
Eli Lilly Raised Its Revenue Guidance for Fiscal 2018
In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 revenue guidance by ~$300 million.
Eli Lilly: Analysts’ Recommendations in August
For Eli Lilly, three analysts recommended a “strong buy,” six recommended a “buy,” and nine recommended a “hold.”
These Products Saw Falling Sales in Pfizer’s Q2 2018
Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market.
What’s the Latest from Bristol-Myers Squibb’s Research Pipeline?
In May, Bristol-Myers Squibb’s Opdivo and Yervoy combination was approved in Japan for previously untreated patients with unresectable melanoma.
Pfizer’s Xeljanz Receives Marketing Authorization in EU
On August 1, Pfizer announced that the European Commission approved Xeljanz for the treatment of ulcerative colitis.
A Performance Overview of Merck’s Virology and Immunology Drugs
In the second quarter of 2018, Merck’s (MRK) Zepatier generated revenues of $113.0 million compared to $517.0 million in the second quarter of 2017.